BIOPHARMA GLOBAL

Eli Lilly extends tender offer to buy Point Biopharma after low participation

In October, Lilly agreed to acquire Point Biopharma in an all-cash deal valued at $1.4 billion to gain access to its experimental therapies that enable precise targeting of cancer.